Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients
NCT ID: NCT06631404
Last Updated: 2024-10-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
55 participants
OBSERVATIONAL
2024-10-01
2025-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
LN is diagnosed by either the presence of proteinuria \>0.5g/day. active urinary sediment , or an unexplained rise in serum creatinine there fore , identifying new invasive biomarkers of LN severity and outcome is mandatory, Renal Arterial resistive index ( RRI) is anon invasive biomarker that has been studied as apotential indicator of disease activity in LN patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Renal Resistive Index as a Marker of Severity and Treatment Outcomes in Lupus Nephritis
NCT03958851
A Study of Clinical Characteristics ,Risk Factors and Outcome of Lupus Nephritis Among Children With Systemic Lupus Erthromatousus in Sohag Univeristy Hospital
NCT06491602
Systemic Immune Inflammatory Index in Systemic Lupus Erythematosus
NCT06796569
Prognostic Factors for Treatment Responses in Patients With Active Lupus Nephritis at Sohag University Hospital
NCT04756492
Urinary Congophilia As an Indicator of Activity of Lupus Nephritis
NCT06654024
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group SLE
Patients with SLE
renal doppler
doppler srudy on renal arteries bilaterally , and detection of RI of renal artery
group control
matched healthy subjects
renal doppler
doppler srudy on renal arteries bilaterally , and detection of RI of renal artery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
renal doppler
doppler srudy on renal arteries bilaterally , and detection of RI of renal artery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* SLE patients fulfilling the SLE International Collaborating Clinics (SLICC) classification criteria and matched controls.
* Patients cooperative and can answer questions.
* Patients who are able and willing to give written informed consent.
Exclusion Criteria
* Diabetes.
* Hypertension.
* Heart failure.
* Hepatic diseases.
* Chronic renal failure.
* Renal artery stenosis.
* Renal vein thrombosis.
* Intrarenal arteriovenous fistula.
* Obstructive nephropathy.
* Urinary tract obstruction that could affect RI of intra renal arteries.
* Un cooperative patients.
* Patients not able and willing to give written informed consent.
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Doaa Rabea Abdelkarim
resident at rheumatology and rehabilitation department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sohag university Hospital
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Esam M Abualfadl, professor
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Magdy M Amin, professor
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Alforaih N, Whittall-Garcia L, Touma Z. A Review of Lupus Nephritis. J Appl Lab Med. 2022 Oct 29;7(6):1450-1467. doi: 10.1093/jalm/jfac036.
Ameer MA, Chaudhry H, Mushtaq J, Khan OS, Babar M, Hashim T, Zeb S, Tariq MA, Patlolla SR, Ali J, Hashim SN, Hashim S. An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management. Cureus. 2022 Oct 15;14(10):e30330. doi: 10.7759/cureus.30330. eCollection 2022 Oct.
Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020 Jan 23;6(1):7. doi: 10.1038/s41572-019-0141-9.
Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol. 2022 Jun;76(6):1362-1378. doi: 10.1016/j.jhep.2022.03.026.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-24-09-07MS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.